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We determined the seroprevalence of severe acute re-
spiratory syndrome coronavirus 2 (SARS-CoV-2) in an 
affected area in northern Iran in April 2020. Antibodies 
to SARS-CoV-2 were detected in 528 persons by using 
rapid tests. Adjusted prevalence of SARS-CoV-2 sero-
positivity was 22.2% (95% CI 16.4%–28.5%).
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Coronavirus disease (COVID-19) was first report-ed in China and has now spread throughout the 
world. Global estimates of disease spread are based 
on confirmed cases in symptomatic patients (1). How-
ever, these estimates do not accurately reflect actual 
infection rates in the community because they exclude 
persons with mild or no symptoms or for whom test-
ing is unavailable. Knowledge about actual infection 
rates is vital for accurately estimating the case-fatality 
rate, a public health measure of COVID-19 (2), and for 
projecting the course of the pandemic and determin-
ing public policy guidelines (3). 
Guilan Province was the second-largest province 
in Iran to have multiple confirmed cases of COVID-19 
soon after the beginning of the pandemic. The 
epidemic curve has subsided in this province, making 
it an appropriate location to test for the presence of 
past infections through a seroprevalence survey. 
In this study, we provided a population-based 
seropositivity estimate of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) infection 
based on World Health Organization protocol.
We conducted a cross-sectional population-based 
study among persons in Guilan Province during 
April 11–19, 2020. The study was approved by the 
Institutional Review Board of Guilan University of 
Medical Sciences (Rasht, Iran). All persons living 
in a household, regardless of age, were invited 
through multistage cluster random sampling. We 
selected clusters from the list of Comprehensive 
Healthcare Centers (CHCs) (the top units of the 
healthcare network in Iran) and used simple random 
sampling method to select households from those 
covered by CHCs. On the day participants arrived 
at the CHC, we took 10 µL capillary blood samples 
from each participant and collected information on 
demographics, disease history, COVID-19 symptoms 
in previous 3 months, and history of SARS-CoV-2 
exposure. Samples were tested by using VivaDiag 
Rapid test kit (VivaChek, https://www.vivachek.
com) for a SARS-CoV-2–specific serologic assay.
The design-adjusted prevalence of seropositivity 
was estimated by using inverse probability weighting 
with weights equal to the inverse of probability of 
selection for each participant (4). The prevalence 
estimates were then adjusted for test characteristics. 
We used a Monte Carlo bias analysis with 100,000 
samples for sensitivity of 83.3% and specificity of 99% 
for IgM or IgG (5,6). The number of infections was 
calculated by multiplying infection prevalence by 
total population of Guilan Province. All analyses were 
performed in Stata version 14 (Stata, https://www.
stata.com). Additional information about methods 
and results has been provided in the Appendix 
(https://wwwnc.cdc.gov/EID/article/27/2/20-
1960-App1.pdf).
Of 632 households contacted, 196 households, 
consisting of a total of 551 persons, participated in this 
study. Eleven of those 551 participants refused blood 
sampling and could not be tested, and 12 had invalid 
test results. Of the remaining 528 participants, 117 were 
positive for either IgM or IgG (22.1% [95% CI 0.19%–
0.26%]). Adjusted for design and test performance, 
prevalence was 22.2% (95% CI 16.4%–28.5%).
Seropositivity prevalence estimates varied most 
substantially according to age group, occupation, 
presence of COVID-19 symptoms in the previous 
3 months, and county of residence (Table). Office 
workers had the highest prevalence of SARS-CoV-2 
infection, followed by taxi drivers. Among counties, 
the highest prevalence of seropositivity was in Anzali, 
followed by Rasht. 
In this study, the seroprevalence estimate of 
SARS-CoV-2 antibodies after adjusting for population 
and test characteristics was 22.2%. This result is 
much higher than those for previous seroprevalence 
estimates using an immunoassay test to detect 
antibodies in Spain (7); California, USA (8); and 
Geneva, Switzerland (9). Unlike Guilan Province, 
those places enacted severe lockdown policies to 
636 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 2, February 2021
RESEARCH LETTERS
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 27, No. 2, February 2021 637
RESEARCH LETTERS
contain the pandemic, which might explain the higher 
prevalence of infection in our study. 
Our study’s limitations include possible 
selection bias if persons with previous COVID-19–
like symptoms sought to participate in the study. 
However, in our study only 11 participants had 
a history of COVID-19 diagnosis. Otherwise, bias 
toward persons in good health who could participate 
in the study might result in an underestimation of 
actual prevalence. In addition, household sampling 
might result in an overestimation of prevalence 
compared with random sampling of persons because 
of clustering of infection in household contacts. We 
excluded persons in institutional residences (i.e., 
nursing homes, boarding schools, and prisons), for 
whom close contact with others might increase risk 
for infection, resulting in an underestimation of 
actual prevalence. Finally, our study used rapid test 
kits that have lower sensitivity than the ELISA test 
method, particularly for patients in the acute phase of 
infection. However, the study was designed to detect 
previous infection in healthy persons, in whom the 
test has better sensitivity. 
In conclusion, our findings imply that ≈518,000 
persons in Guilan Province may have been infected 
with SARS-COV-2 as of April 19, 2020, which is 
substantially higher than the 1,600 cumulative 
confirmed cases recorded. As of May 3, if we assume 
a 3-week lag from time of infection to death (10), 625 
persons had died of confirmed COVID-19 in Guilan 
Province. This number would correspond to an 
infection-fatality rate of 0.12%.
 
Table. Severe acute respiratory syndrome coronavirus 2 seropositivity prevalence estimates according to study variables, Guilan 
Province, Iran, April 2020* 
Characteristic 
Sample size (%), 





Design- and test performance–
adjusted prevalence (95% CI†) 
Sex     
 M 257 (48.7) 55 16.8 (13.2–21.2) 19.0 (12.7–25.4) 
 F 271 (51.3) 62 22.2 (14.7–32.1) 25.6 (15.4–36.8) 
Age group, y     
 <5 26 (4.9) 4 8.7 (2.1–30.2) 9.8 (0.9–22.6) 
 5–17 101 (19.1) 20 17.0 (11.6–24.2) 19.1 (11.2–27.5) 
 18–59 329 (62.3) 74 21.0 (16.9–25.8) 24.1 (17.5–31.6) 
 ≥60 72 (13.6) 19 22.4 (15.7–31.0) 25.7 (16.6–36.1) 
Obesity, BMI >30     
 No 474 (89.8) 107 19.8 (16.9–22.9) 22.6 (16.8–29.0) 
 Yes 54 (10.2) 10 15.4 (7.8–28.2) 17.3 (6.2–29.0) 
SARS-CoV-2 exposure history     
 No 452 (85.6) 95 18.1 (12.7–25.1) 20.4 (12.6–28.8) 
 Yes 76 (14.4) 22 26.9 (13.5–46.5) 31.2 (13.4–50.8) 
COVID-19 symptoms in previous 3 mo    
 No 382 (69.3) 65 15.3 (11.03–20.9) 17.2 (10.3–24.1) 
 Yes 169 (30.7) 52 30.05 (25.3–36.4) 35.5 (27.8–45.8) 
Underlying condition     
 No 420 (79.5) 89 18.2(13.6–24.03) 20.7 (13.5–28.3) 
 Yes 108 (20.5) 28 25.3 (18.3–33.9) 29.2 (19.8–40.2) 
Place of residence     
 Village 162 (30.7) 38 21.0 (16.0–27.1) 24.0 (16.5–32.4) 
 Town 366 (69.3) 79 19.2 (16.0–23.0) 21.9 (15.8–28.4) 
Occupation‡     
 Employee 53 (10.04) 19 46.0 (35.9–56.5) 54.3 (41.8–71.1) 
 Housekeeper 159 (30.1) 39 21.8 (13.4–33.5) 25.0 (13.6–37.5) 
 Student 114 (21.6) 22 15.6 (12.1–20.0) 17.5 (11.3–23.7) 
 Unemployed 67 (12.7) 11 11.8 (7.6–18.0) 12.9 (5.9–19.6) 
 Farmer 16 (3.03) 3 17.4 (9.9–28.8) 19.7 (9.1–31.0) 
 Salesman 46 (8.7) 5 7.9 (2.0–26.7) 8.7 (0.8–20.0) 
 Healthcare personnel 43 (8.1) 12 13.2 (6.5–24.9) 14.5 (4.5–25.0) 
 Taxi driver 13 (2.5) 5 24.0 (7.1–56.7) 28.0 (4.5–56.3) 
 Worker 17 (3.2) 1 2.5 (0.1–32.1) 28.0 (4.5–56.3) 
County     
 Rasht 226 (42.8) 56 20.8 (19.7–21.9) 23.7 (18.6–29.6) 
 Anzali 75 (14.2) 23 30.0 (29.7–30.4) 34.8 (29.7–43.2) 
 Astara 78 (14.8) 12 15.4 (14.3–16.6) 17.4 (12.0–21.8) 
 Lahijan 74 (14) 12 15.0 (13.6–16.5) 16.9 (11.5–21.4) 
 Rudbar 75 (14.2) 14 17.7 (15.5–20.2) 20.1 (14.5–25.7) 
*BMI, body mass index; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.  
†Calculated using Monte Carlo simulation method.  
‡Employee was defined as a government employee working in an office. Worker was defined as a person performing manual jobs in nongovernmental 
locations. 
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We documented fetal death associated with intrauter-
ine transmission of severe acute respiratory syndrome 
coronavirus 2. We found chronic histiocytic intervillosi-
tis, maternal and fetal vascular malperfusion, microglial 
hyperplasia, and lymphocytic infiltrate in muscle in the 
placenta and fetal tissue. Placenta and umbilical cord 
blood tested positive for the virus by PCR, confirming 
transplacental transmission.
